What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report Eli Lilly's financial results for the second quarter and the first six months of 2007. It also includes the company's financial guidance for the remainder of the year.

What are 'adjusted pro forma' results, and why is Lilly using them?

Adjusted pro forma results are non-GAAP financial measures that exclude certain items, such as charges from acquisitions (like Hypnion, Ivy Animal Health, and ICOS) and restructuring costs. Lilly uses these to provide investors with a clearer view of ongoing operational performance and to facilitate more meaningful period-over-period comparisons, as these excluded items can be large and unpredictable.

What key acquisitions are impacting the financial results and adjustments?

The filing specifically mentions the acquisitions of Hypnion, Inc., Ivy Animal Health, and ICOS Corporation as contributing to the in-process research and development charges that are being excluded from adjusted results. The ICOS acquisition is also being presented on a pro forma basis as if it occurred in early 2006 for comparative analysis.

Where can I find the detailed financial results mentioned in this filing?

The detailed financial results, including the income statement and the discussion of adjusted pro forma measures, are provided in the press release dated July 24, 2007, which is attached to this Form 8-K as Exhibit 99.1.

LLY 8-K: Earnings & Results

Summary

Eli Lilly & Co. (LLY) filed an 8-K on July 24, 2007, primarily to report its second-quarter and year-to-date financial results for 2007. The report highlights the company's use of non-GAAP financial measures, such as adjusted net income and adjusted earnings per share, to provide a clearer view of ongoing operational performance. These adjustments exclude significant charges related to acquisitions (Hypnion, Ivy Animal Health, and ICOS Corporation) and restructuring activities. Investors are encouraged to consider these adjusted figures alongside GAAP results for a more comprehensive understanding of trends and performance. The filing also includes forward-looking financial expectations for the third quarter and the full year 2007, presented on both GAAP and adjusted pro forma bases. The company's rationale for using these non-GAAP measures is to offer investors more meaningful period-over-period comparisons and to identify underlying operational trends that might otherwise be obscured by one-time charges or acquisition-related accounting. The press release detailing these results is attached as an exhibit.

Key Highlights

1Eli Lilly reported its Q2 and year-to-date 2007 financial results via an 8-K filing on July 24, 2007.
2The company is utilizing non-GAAP financial measures (adjusted net income, adjusted EPS) for enhanced performance analysis.
3Adjustments exclude significant charges from acquisitions (Hypnion, Ivy Animal Health, ICOS) and restructuring activities.
4A pro forma presentation is used, including the ICOS acquisition as if it occurred on January 1, 2006, for comparative purposes.
5The filing provides financial expectations for Q3 and full-year 2007, both on GAAP and adjusted pro forma bases.
6Lilly emphasizes that non-GAAP measures aid in understanding ongoing operations and identifying trends.
7The press release with detailed financial results and commentary is attached as Exhibit 99.1.

ELI LILLY & Co 8-K Report, Financial Results (Jul 24, 2007)

Summary

Key Highlights

Frequently Asked Questions